Loading
A phase 1/2 trial of MT218 injection in prostate cancer, run by Songqi Gao, now recruiting.
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients is a phase 1/2 interventional study registered as NCT06262139 by Songqi Gao, with 12 participants planned, started 2024-07-25 and due to reach its primary completion in 2026-12. Interventions recorded: MT218 injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/